The phosphoprotein tyrosine phosphatase SHP-1 (encoded by the <i>Ptpn6</i> gene) has been proposed as an immune checkpoint in CD8<sup>+</sup> T cells in preclinical models, yet its pharmacological inhibition has shown no efficacy against tumor growth in clinical trials. Here, PTPN6 is linked to neoplasm.